GlassScriptPhysician profile
Ashikkumar Ambalal Raval
NPI 1871688713
$261.23
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.82 · 2020: $173.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $54.39 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $41.13 | 2019-2020 | |
| Amarin Pharma, INC. | $23.81 | 2019 | |
| Genentech USA, INC. | $18.04 | 2020 | |
| Glaxosmithkline, LLC. | $17.91 | 2020 | |
| Seqirus USA INC | $17.87 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.19 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.24 | 2020 | |
| Merck Sharp & Dohme LLC | $16.24 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.07 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $13.28 | 2020 | |
| Novo Nordisk INC | $11.06 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashikkumar Raval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.